MEDIPOST Completes Phase 2a Clinical Trial of NEUROSTEM for Alzheimer’s Disease2020/07/07STEM CELL THERAPEUTIC
MEDIPOST’s Clinical Trial of Next-Generation Cell Therapy Product ‘SMUP-IA-01’ Makes Solid Progress2020/05/21STEM CELL THERAPEUTIC
MEDIPOST Completes Phase 2a Clinical Trial of NEUROSTEM for Alzheimer’s Disease2020/01/06STEM CELL THERAPEUTIC
MEDIPOST Clears Phase II Clinical Trial Approval for CARTISTEM in Japan2019/12/09STEM CELL THERAPEUTIC
MEDIPOST Receives Approval for Phase III Clinical Trial of CARTISTEM for the Treatment of Osteochondral Cartilage Defects in Ankle Joint2019/12/03STEM CELL THERAPEUTIC
MEDIPOST to Expand the GMP facility to increase manufacturing capacity for CARTISTEM and new pipeline of products2019/11/14STEM CELL THERAPEUTIC
MEDIPOST Registers the Chinese Patent for a Mesenchymal Stem Cell Culture Method2019/10/23STEM CELL THERAPEUTIC
MEDIPOST Treats First Patient with Injectable Cell Therapeutic for Knee Osteoarthritis2019/10/17STEM CELL THERAPEUTIC
MEDIPOST Registers European Patent for the Mesenchymal Stem Cell Culture Method2019/07/24STEM CELL THERAPEUTIC
MEDIPOST Registers the Canadian Patent for a Mesenchymal Stem Cell Culture Method2019/06/26STEM CELL THERAPEUTIC
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022/10/17
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products2022/05/31
